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Abstract
Background:  Warfarin treatment has a narrow therapeutic range, requiring meticulous
monitoring and dosage titration. Individual dosage requirement has recently partly been explained
by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating
enzyme VKORC1. In the WARIS-II study, comparing three different antithrombotic regimens after
myocardial infarction, warfarin treatment reduced thrombotic events, but was associated with
more frequent bleeding than use of acetylsalisylic acid (ASA) alone.
Aims: The primary aim of the present study was to investigate the relation between genotypes of
CYP2C9 and VKORC1 and warfarin maintenance dose in myocardial infarction. The secondary aim
was to relate the genotypes to international normalized ratio (INR).
Methods: Genotyping was performed in 212 myocardial infarction patients from the WARIS-II
study by robotic isolation of DNA from EDTA whole blood (MagNa Pure LC) before PCR
amplification (LightCycler) and melting point analysis.
Results: The 420 C>T substitution of CYP2C9*2, the 1075 A>C substitution of CYP2C9*3 and
the 1173 C>T substitution of VKORC1 had minor allele frequencies of, 11.3%, 5.7% and 36.6%
respectively. Warfarin weekly dose varied between 17 mg and 74 mg among the patients. INR did
not vary between genotypes. Warfarin dosage requirement was significantly associated with
CYP2C9 and VKORC1 genotypes, treatment group and age. The VKORC1 genotype contributed
24.5% to the interindividual variation in warfarin dosage, whereas the combined CYP2C9
genotypes were only responsible for 7.2% of the dose variation.
Conclusion: CYP2C9 and VKORC1 genotype frequencies in myocardial infarction patients appear
similar to other patient groups and have similar impact on warfarin maintenance dose.
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Background
Warfarin and aspirin (ASA) have a well established role in
secondary prevention of atherothrombotic disease, reduc-
ing new thromboembolic events [1-4]. However, response
to anticoagulant treatment varies between individuals,
requiring careful monitoring in order to keep interna-
tional normalized ratio (INR) within a narrow therapeutic
range. In spite of adherence to dosage regimens, INR val-
ues have been observed to be outside the target range 50%
of the time [5,6], and this could possibly lead to treatment
failure or adverse events. An important issue is to improve
anticoagulation treatment in order to avoid thrombosis
and treatment-induced bleeding.
Warfarin antagonizes the vitamin K-dependent activation
of a range of coagulation factors (II, VII, IX, X) and antico-
agulants (protein C, protein S), and INR is used as an indi-
cator of coagulation status. Two gene products known to
influence warfarin dose are the enzymes Cytochrom P 450
subtype 2C9 (CYP2C9) and the Vitamin K Epoxide
Reductase 1 (VKORC1), which are involved in drug
metabolism and vitamin K activation, respectively. Com-
mon gene polymorphisms exist for both enzymes, result-
ing in marked alteration of enzyme activity, and several
studies have characterized the role of these polymor-
phisms in explaining a substantial part of the variation in
warfarin dosage requirement [7-15]. In the study of Aithal
et al. [16], carriers of CYP2C9 gene polymorphisms were
affected by bleeding complicatins more often than non-
carriers during warfarin treatment.
In the WARIS-II study, warfarin alone or in combination
with low dose ASA (75 mg daily) were superior to 160 mg
ASA in prevention of new thrombotic events after acute
myocardial infarction, but was also associated with higher
risk of bleeding [17]. Thus, 15.0 – 16.7% of the patients
in the warfarin groups experienced the primary endpoint
(new thrombotic events or fatal bleeding) and 11.3–
13.1% experienced minor or major nonfatal bleeding dur-
ing four years treatment. In comparison, ASA alone
resulted in new thrombotic events in 20% of the patients
and minor or major nonfatal bleeding in 4.0%. It is not
known whether different frequencies of gene polymor-
phisms in the treatment groups contributed to the differ-
ences in bleeding risk.
The primary aim of the present study was to investigate
the relation between genotypes of CYP2C9 and VKORC1
and warfarin maintenance dose in myocardial infarction
patients (from the WARIS-II study). The secondary aim
was to relate the genotypes to international normalized
ratio (INR).
Methods
Patients
This substudy was established from the Warfarin Aspirin
Reinfarction Study (WARIS-II), a Norwegian multicenter
study, comparing three different antithrombotic regimens
on clinical end-points of mortality, reinfarction and cere-
bral stroke after acute myocardial infarction [17]. All
patients provided written informed consent before partic-
ipation in the study. Three groups of patients were ran-
domly assigned to treatment with either a daily dose of
160 mg ASA (Albyl E, Nycomed Pharma, Norway), warfa-
rin (Marevan, Nycomed Pharma) with a target interna-
tional normalized ratio (INR) of 2.8 to 4.2, or 75 mg of
ASA combined with warfarin (target INR 2.0 – 2.5) and
followed for 4 years. Coagulation status of the warfarin
patients was controlled by recording INR systematically.
The present population consisted of totally 212 patients
from the Oslo subset of the study at Ullevaal University
Hospital, from whom we acquired blood samples for gen-
otyping. In 105 of these, INR values and weekly warfarin
dose were also available (58 in the warfarin group (W),
and 47 in the W+ASA group). All bleeding episodes were
registered throughout the study period [18].
Genotyping
DNA was isolated from 200 μl EDTA whole blood by
MagNA Pure LC robot [19] according to the manufac-
turer's instructions using MagNA Pure LC DNA High Per-
formance isolations kit (Roche cat no 03003990001).
DNA was amplified by polymerase chain reaction (PCR)
on a real-time fluorescence LightCycler instrument [19] in
a final volume of 20 μl using a LightCycler Faststart DNA
Master Hybridization Probe Kit (Roche cat no
12239272001) with primers and probes specific for
selected single nucleotide polymorphisms (SNPs) local-
ized in the CYP2C9 and VKORC1 genes. Genotypes were
determined by melting point analyses. PCR conditions
were essentially containing FastStart Reaction Mix includ-
ing FastStart Taq Polymerase, 3 mM MgCl2 and 50–100 ng
genomic DNA.
Genotyping the two functional sequence variants
CYP2C9* 2 and CYP2C9*3 in the human CYP2C9 gene
(GenBank accession number AY702706) was performed
essentially as described by others [20], except for the use
of double probe concentration (0.4 μM) in the
CYP2C9*2-assay. The CYP2C9*2 allele is a C to T substi-
tution in nucleotide position 420 in exon 3, leading to an
amino acid shift from arginine to cysteine in position 144.
The CYP2C9*3 variant is an A to C shift in nucleotide
position 1075 in exon 7, resulting in an amino acid
change from isoleucine to leucine in position 359.
From common and publicly available sequence variants
in the human VKORC1 gene (GenBank accession numberThrombosis Journal 2008, 6:7 http://www.thrombosisjournal.com/content/6/1/7
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AY587020), we selected one SNP (rs9934438/1173 C>T)
localized in the first intron of VKORC1, reported to have
a minor allele frequency (MAP) of about 40% [8] and to
be in strong linkage disequilibrium with three other SNPs
(rs9923231/17878363, rs8050894 and rs2359612).
Patients carrying the rs9934438 variant have been shown
to require less warfarin dosages [14] and Geisen et al. [15]
suggested these four SNPs to be combined in a common
VKORC1*2 haplotype, corresponding as a marker for low
warfarin requirement. The forward and reverse primers
were 5'-AAAAGCAGGGCCTACG-3' and 5'-CCGAGAAAG-
GTGATTTCCA-3', respectively. LCRed640-labelled sensor
probe was 5'-CGACCCTTGGACTAGGATGG-3', whereas
the anchor probe was 5'-GCCCGGTGCCAGGAGATC-3'
[21]. The primer concentration was 0.5 μM, whereas the
anchor and sensor probe concentrations were 0.4 μM and
0.2 μM, respectively. The following cycle conditions were
used: 10 min denaturation at 95°C before 35 cycles at
95°C for 10 s, 60°C for 10 s and 70°C for 5 s. Melting
conditions were 95°C for 0 s, 45°C for 30 s and tempera-
ture transition from 45°C to 85°C (0.1°C/s).
PCR primer and probe sequences were tested for homol-
ogy with other sequences at the NCBI gene BLAST website
[22]. All assays were validated by sequencing the PCR frag-
ments for the different SNPs before genotyping the
patients. Positive mutation controls and negative controls
were included in every run.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 statistic
software (SPSS Inc., Chicago, IL, USA). Univariate and
stepwise multiple regression analyses were performed to
evaluate the impact of polymorphisms in VKORC1 and
CYP2C9 genes on mean warfarin dose, after adjustment
for the covariates age, sex and treatment group. The signif-
icance level of P ≤ 0.05 was set for entry into the model
and P ≥ 0.10 for removal from the model.
Results
Patient characteristics
A total of 212 Caucasian patients, divided into three dif-
ferent anticoagulation regimens (see Materials and Meth-
ods) were genotyped for common VKORC1 and CYP2C9
polymorphisms in this study. One hundred and five
patients were included in the two warfarin groups. The
treatment groups were similar as to baseline characteris-
tics (age, sex). Noteworthy, there was a statistically signif-
icant (P = 0.005, Mann-Whitney test) difference in mean
warfarin dose between the warfarin and warfarin +ASA
groups (41.7 mg/week vs. 34.4 mg/week, respectively).
This difference reflects the differences in observed INR val-
ues 2.4–3.6 (mean 3.1) and 1.9–2.9 (mean 2.2) for war-
farin and warfarin +ASA groups, respectively and in INR
target values of 2.8–4.2 and 2.0–2.5, respectively.
CYP2C9 and VKORC1 genotypes
Genotype distributions of CYP2C9*2, CYP2C9*3 and
VKORC1 1173 C>T polymorphisms in 212 patients from
the Oslo subset of the WARIS-II study are summarized in
Table 1. The frequencies of homozygotes for the *2 and
*3 CYP2C9-variants were as expected low (1.9 and 0.5%,
respectively), whereas homozygotes of VKORC1 1173
C>T (T/T) was 13.2%. The frequencies of the two hetero-
zygous genotypes CYP2C9*1/*2 and CYP2C9*1/*3 were
17.9% and 9.4%, respectively, whereas compound heter-
ozygotes of CYP2C9*2/*3 was 0.9%. VKORC1 1173 C>T
heterozygotes was 46.7%. Minor allele frequencies (MAF)
Table 1: Genotype distributions of VKORC1 1173 C>T, CYP2C9*2 and CYP2C9*3 polymorphisms in the investigated patients (MAF = 
minor allele frequency).
Genotype Total material N = 212 Warfarin N = 58 ASA N = 72 Warfarin + ASA N = 47
Number of 
patients 
(genotype 
frequency in %)
MAF (%) Number of 
patients 
(genotype 
frequency in %)
MAF (%) Number of 
patients 
(genotype 
frequency in %)
MAF (%) Number of 
Patients 
(genotype 
Frequency in %)
MAF (%)
VKORC1
1173 C>T 36.6 40.5 36.1 33.0
CC 85 (40.1) 20 (34.5) 30 (41.7) 23 (48.9)
CT 99 (46.7) 29 (50.0) 32 (44.4) 17 (36.2)
TT 28 (13.2) 9 (15.5) 10 (13.9) 7 (14.9)
CYP2C9
*1/*1 147 (69.3) 40 (69.0) 48 (66.7) 33 (70.2)
*1/*2 38 (17.9) 11.3 12 (20.7) 11.2 10 (13.9) 7.6 8 (17.0) 17.0
*2/*2 4 (1.9) - - 4 (8.5)
*1/*3 20 (9.4) 5.7 5 (8.6) 5.2 12 (16.7) 10.4 2 (4.3) 2.1
*3/*3 1 (0.5) - 1 (1.4) -
*2/*3 2 (0.9) 1 (1.7) 1 (1.4) -Thrombosis Journal 2008, 6:7 http://www.thrombosisjournal.com/content/6/1/7
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of the CYP2C9*2 and CYP2C9*3-variants were 11.3 and
5.7%, respectively, and of the VKORC1 36.6%. The geno-
type frequency of the CYP2C9*1/*2 variant was 20.7% in
the warfarin group and 17.0% in the warfarin + ASA
group, whereas the CYP2C9*1/*3 variant was 8.6% in the
warfarin group and 4.3% in the warfarin + ASA group.
VKORC1 heterozygote genotype frequency was 50.0% in
the warfarin group and 36.2% in the warfarin+ASA group.
Homozygotes of the CYP2C9*2 variant were not present
in the warfarin group, but constituted 8.5% of the warfa-
rin + ASA group. CYP2C9 compound heterozygotes
(CYP2C9*2/*3) was 1.7% in the warfarin group, but
absent in the warfarin + ASA group. MAF frequencies for
the *2 og *3 variants of CYP2C9 and VKORC1 in the war-
farin group were 11.2, 5.2 and 40.5%, respectively, and
17.0, 2.1 and 33.0% for the respective variants in the war-
farin + ASA group.
Associations of CYP2C9 and VKORC1 polymorphisms with 
warfarin dose and INR
Relation between warfarin dose and CYP2C9 and
VKORC1 genotypes is illustrated in Figure 1. The investi-
gated polymorphisms in CYP2C9 or VKORC1 were asso-
ciated with marked reduction in warfarin dosage
requirements. Carriers of CYP2C9 polymorphisms with
wildtype VKORC1 genotype (C/C) show almost similar
reduction in dose requirement as carriers of VKORC1 pol-
ymorphism with wildtype CYP2C9 (*1/*1). Results of the
stepwise multivariate regression analysis of the two warfa-
rin groups (totally 105 patients; 58 warfarin; 47 warfarin
+ ASA) are given in Table 2. All three polymorphisms of
CYP2C9 and VKORC1 covaried significantly with warfa-
rin dose according to the regression model. The investi-
gated VKORC1 polymorphism showed closest association
with the variation in warfarin dose, explaining 24.5% of
the interindividual variability, whereas the two CYP2C9
polymorphisms in combination contributed to 7.2% of
the dose variation. Age accounted for 4.2% of the total
dose variability, whereas sex did not contribute to dose
variation.
INR values did not vary significantly between different
genotypes as shown in Table 3. There were observed 2
major, 7 minor and 14 occult bleeding episodes in the
present material of 105 warfarin-treated patients. As
shown in Table 3, there is a trend for more bleeding epi-
Box plot of mean weekly warfarin doses for different genotypes of VKORC1 1173 C>T and CYP2C9 *1,*2 and *3 Figure 1
Box plot of mean weekly warfarin doses for different genotypes of VKORC1 1173 C>T and CYP2C9 *1,*2 and 
*3. The box represents the values from the 25 to 75% percentile. The middle line represents the median. The vertical line 
extends from the minimum to the maximum value, excluding outlier and extreme values which are marked as open circles and 
an asterisk respectively.Thrombosis Journal 2008, 6:7 http://www.thrombosisjournal.com/content/6/1/7
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sodes in patients with the C/T VKORC1 genotype. There
were 2 major, 6 minor and 7 occult bleeding episodes in
the warfarin group in comparison with one minor and 7
occult bleeding episodes in the warfarin + ASA group, a
difference that could be related to higher INR (0.9 unit) in
the warfarin group.
Discussion
This study was designed to investigate the frequency of
CYP2C9 and VKORC1 gene polymorphisms and their
relation to warfarin dose and INR in patients with myo-
cardial infarction from the Norwegian WARIS-II study.
The genotype and allele frequencies of CYP2C9 and
VKORC1 polymorphisms for the whole group of 212
patients investigated were in accordance with recent
reports from studies in Caucasians. The relation observed
between polymorphisms of CYP2C9 and VKORC1 and
variation in warfarin dose requirement was as previously
reported in other patient groups.
The minor allele frequencies (MAF) of 37% for the
VKORC1 polymorphism 1173C>T, 11% for the
CYP2C9*2 and 6% for the CYP2C9*3 were all slightly
lower than those reported by Takahashi, who found MAF
of 42, 14 and 10% for the respective polymorphisms in
Caucasians [9]. The results from the multivariate analysis
of the present 105 Norwegian patients of Caucasian race
confirmed previous studies with regard to apparent influ-
ence of the genotypes on warfarin dosage requirement,
the VKORC1 polymorphism having the larger impact
(25%) compared to CYP2C9 (7%). In a group of 201
Swedish patients, VKORC1 contributed 29% and CYP2C9
12% [8]. Another study performed with 165 Slovenians
showed that VKORC1 contributed 34% and CYP2C9 18%
[23]. As recently reviewed by Wadelius and Pirmohamed
[24], six studies found a greater relative contribution of
VKORC1 than CYP2C9 [8-10,12,13,15]; two studies
found that CYP2C9 had a greater contribution [11,14],
and one study found equal contribution from the two pol-
ymorphisms [7]. The relative contribution of each poly-
morphism to variation in warfarin dosage requirement in
the whole group of patients must be considered in rela-
tion to the frequencies of the polymorphisms. Conse-
quently, VKORC1 likely contributes more than CYP2C9
due to markedly higher frequency of the 1173C>T poly-
morphism than of the CYP2C9*2 and CYP2C9*3 poly-
Table 2: Multiple regression analysis of mean weekly warfarin dose (mg) related to genotypes, treatment group and age. Coefficients 
and significance levels are listed for each predictor. R2 values indicate the cumulative contribution of each predictor as they are 
entered into the model. P-value for the model was <0.0001.
Predictor Warfarin dose (mg) Significance Adjusted R2 (cumulative)
Constant 72.297 P < 0.001
VKORC1 1173 T/T -18.946 P < 0.001 0.101
VKORC1 1173 C/T -11.930 P < 0.001 0.245
Treatment group -8.540 P < 0.001 0.358
CYP2C9 *1/*2,*3 -7.275 P = 0.001 0.398
CYP2C9 *2/*2,*3 -15.459 P = 0.001 0.430
Age -0.321 P = 0.004 0.472
Dose [mg/week] = 72.297 - 18.946 · (T/T) -11.930· (C/T) - 8.540 · (group) -7.275 · (*1/*2,*3) - 15.459 · (*2/*2,*3) - 0.321· (age)
Table 3: Bleeding events according to CYP2C9 and VKORC1 genotype.
CYP2C9 
genotype
VKORC1 
genotype
N (%) Mean INR 
(95% C.I.)
Major/minor bleeding 
events N (%)
Occult bleeding 
events N (%)
Total bleeding 
events N (%)
*1/*1 C/C 33 (31.4) 2.65 (2.45–2.84) 2 (6.1) 4 (12.1) 6 (18.2)
C/T 28 (26.7) 2.79 (2.60–2.99) 3 (10.7) 5 (17.9) 8 (28.6)
T/T 12 (11.4) 2.71 (2.37–3.05) 2 (16.7) - 2 (16.7)
*1/*2,*3 C/C 8 (7.6) 2.58 (2.19–2.96) - 1 (12.5) 1 (12.5)
C/T 16 (15.2) 2.83 (2.55–3.10) 2 (12.5) 4 (25.0) 6 (37.5)
T/T 3 (2.9) 2.87 (2.49–3.25)
*2/*2,*3 C/C 2 (1.9) 2.30 (1.03–3.57)
C/T 2 (1.9) 2.15 (0.24–4.06)
T/T 1 (1.0) 3.50
Total 105 
(100)
91 4 2 3Thrombosis Journal 2008, 6:7 http://www.thrombosisjournal.com/content/6/1/7
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morphisms. However, in the individual patient, the
CYP2C9*2 and especially the CYP2C9*3 polymorphism
will be expected to influence warfarin dosage requirement
markedly [25]. This is in accordance with our data, show-
ing equal impact on warfarin dosage variation from poly-
morphisms in VKORC1 and CYP2C9 when investigated
separately (Figure 1).
A meta-analysis of 33 studies showed that major and fatal
bleedings occurred at rates of 7.2 and 1.3, respectively, per
100 patients years during oral anticoagulant therapy [26].
Aithal et al. [16] found that carriers of CYP2C9 polymor-
phisms had higher occurrence of bleeding than non-carri-
ers during warfarin treatment. Carriers of alleles coding
for reduced CYP2C9 and/or VKORC1 enzyme activity,
requiring lower warfarin doses, have been observed to be
more difficult to titrate to a stable maintenance dose than
those needing larger doses [27]. A meta-analysis of
CYP2C9 genetic polymorphisms showed that the relative
bleeding risk was 1.91 for CYP2C9*2 and 1.77 for
CYP2C9*3. For either variant, the relative risk was 2.26
[28]. This suggests that polymorphism carriers have a pre-
disposition for bleeding complications during therapy
[29]. When considering the occurrence of bleeding epi-
sodes in different genotypes (Table 3), it is obvious that
this study is underpowered to detect differences in bleed-
ing risk. Nevertheless, it appears to be more bleeding epi-
sodes in patients with the C/T VKORC1 genotype as
shown in Table 3.
The possible impact of the warfarin dose-related polymor-
phisms on risk of myocardial infarction has recently been
studied. Yasar et al. found a higher risk of myocardial inf-
arction in individuals carrying the *2 or *3 variants of
CYP2C9 [30], whereas Funk et al. [31] found that the *2
and *3 allele variants of CYP2C9 were associated with a
lower risk of myocardial infarction in males (Odds Ratio
0.56), but not in females. Wang et al. [32] found a signif-
icant association between the rs2359612/2255 C>T
VKORC1 polymorphism (a polymorphism found to be in
strong linkage disequilibrium with rs9934438/1173 C>T)
and the risk of coronary heart disease (Odds Ratio for C
carriers 1.72). Obviously, more studies are needed to
investigate the relationship between genotypes, risk of
thromboembolic events (coronary heart disease and myo-
cardial infarction) and treatment-induced bleeding.
In conclusion, the observed genotype frequencies of
CYP2C9 and VKORC1 in patients with myocardial infarc-
tion are similar to those previously reported in other
patient groups and healthy subjects in Caucasians, as is
the relation between warfarin dosage and genotypes. Gen-
otyping would be of value for secondary stratification of
patients into comparable study groups when testing dif-
ferent treatment regimens. The relation between gene pol-
ymorphisms and bleeding frequency during warfarin
treatment needs to be further investigated in larger studies
with sufficient statistical power.
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